Results 251 to 260 of about 651,453 (295)

Emergency Department Utilization for Acute Myocardial Infarction, U.S., May-September 2018-2023. [PDF]

AJPM Focus
Havor EM, Richardson LC, Imoisili OE, Coronado F, Jackson SL, Gates AL, Radhakrishnan L, Vaidyanathan A, Loustalot F, Thompson-Paul AM, Woodruff RC.   +10 more
europepmc   +1 more source

Machine learning-based prediction of mortality in acute myocardial infarction with cardiogenic shock

Qitian Zhang, Lizhen Xu, Zhiyi Xie, Weibin He, Xiaohong Huang   +4 more
openalex   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Risk factors for new-onset atrial fibrillation in patients with acute myocardial infarction. [PDF]

Am J Transl Res
Ge X, Tao Y, Wang Q.
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock. [PDF]

Eur Heart J Cardiovasc Pharmacother
Elhadad A, Sulman D, Procopi N, Devos P, Beaupré F, Braik N, Giovachini L, Charleux P, Combes A, Chommeloux J, Ecollan P, Rouanet S, Kerneis M, Silvain J, Montalescot G, Zeitouni M.   +15 more
europepmc   +1 more source

The safety of enoxaparine use in elderly with acute myocardial infarction

, 2007
Nebojsa Despotovic, Goran Loncar, Maja Nikolic-Despotovic, Marjan Ilic, Siniša Dimković   +4 more
openalex   +2 more sources

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Differential expression of glycolysis-related genes and their potential immune mechanisms in acute myocardial infarction. [PDF]

J Cardiothorac Surg
Li YM, Zhang KZ, Li QH, Qian YR, Li JW, Gao W, Zhou BJ.   +6 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source